Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521508 | 0.85 | TDP1 (0.48) | TSHRALDH1A1CYP3A4RECQLTDP1 | |
| SCHEMBL30578482 | 0.84 | TSHR (0.59) | TSHRALDH1A1CYP3A4RECQLGAA | |
| SCHEMBL17580458 | 0.84 | ALDH1A1 (0.47) | TSHRALDH1A1CYP3A4TDP1MAPT | |
| SCHEMBL11207797 | 0.84 | TSHR (0.59) | TSHRALDH1A1CYP3A4RECQLGAA | |
| SCHEMBL440478 | 0.84 | ALDH1A1 (0.53) | TSHRALDH1A1CYP3A4RECQLGAA | |
| SCHEMBL29525219 | 0.84 | ALDH1A1 (0.53) | TSHRALDH1A1CYP3A4RECQLGAA | |
| SCHEMBL500039 | 0.82 | TDP1 (0.50) | TSHRALDH1A1CYP3A4RECQLTDP1 | |
| SCHEMBL397387 | 0.82 | ATM (0.50) | TSHRALDH1A1CYP3A4RECQLTDP1 | |
| SCHEMBL8095561 | 0.82 | MAPT (0.50) | TSHRALDH1A1CYP3A4TDP1MAPT | |
| SCHEMBL2471756 | 0.82 | ALDH1A1 (0.47) | TSHRALDH1A1CYP3A4RECQLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981873-B | Preparation method for synthesizing pyrroloquinoline quinone by five-step method | 江西农业大学 | 2025-01-24 | — | — | CN | claimed |
| CN-111087395-A | Preparation method for synthesizing pyrroloquinoline quinone by four-step method | 江西农业大学 | 2020-05-01 | — | — | CN | claimed |
| CN-110981873-A | Preparation method for synthesizing pyrroloquinoline quinone by five-step method | 江西农业大学 | 2020-04-10 | — | — | CN | claimed |
| CN-101544589-B | Preparation for medicinal intermediate 6-chloro-5-fluroindole for synthesizing anti-cancer medicament | Shanghai titan chemical co ltd | 2011-11-23 | — | — | CN | claimed |
| CN-101544589-A | Preparation for medicinal intermediate 6-chloro-5-fluroindole for synthesizing anti-cancer medicament | Shanghai titan chemical co ltd | 2009-09-30 | — | — | CN | claimed |
| EP-4680236-A2 | 3-ALKYLAMINE INDOLE ACTIVATORS OF SEROTONIN RECEPTORS | ATAI Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| CN-119954709-A | Preparation method of sulfoxide compound, aniline compound and preparation method of aniline compound | 帕潘纳(北京)科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-110981873-B | Preparation method for synthesizing pyrroloquinoline quinone by five-step method | 江西农业大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-110981873-B | Preparation method for synthesizing pyrroloquinoline quinone by five-step method | 江西农业大学 | 2025-01-24 | — | — | CN | disclosed |
| WO-2024192150-A2 | 3-ALKYLAMINE INDOLE ACTIVATORS OF SEROTONIN RECEPTORS | Atai Therapeutics Inc. (US) | 2024-09-19 | — | — | WO | disclosed |
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | LUPIN LIMITED (IN) | 2024-04-09 | — | — | US | disclosed |
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | KURES, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-2125683-A1 | 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS | The Board of Trustees of the University of Illinois (US) | 2009-12-02 | — | — | EP | disclosed |
| CN-101544589-A | Preparation for medicinal intermediate 6-chloro-5-fluroindole for synthesizing anti-cancer medicament | Shanghai titan chemical co ltd | 2009-09-30 | — | — | CN | disclosed |
| CN-101544589-A | Preparation for medicinal intermediate 6-chloro-5-fluroindole for synthesizing anti-cancer medicament | Shanghai titan chemical co ltd | 2009-09-30 | — | — | CN | disclosed |
| WO-2008077138-A1 | 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008077138-A1 | 3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-06-26 | — | — | WO | disclosed |
| US-6380238-B1 | FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-30 | — | — | US | disclosed |
| EP-1109784-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012475-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | CDKL5, KMT5A, CDKL1 | TSHR 4254/4885ALDH1A1 1878/4885CYP3A4 2371/4885 |
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | TSHR 3684/4885ALDH1A1 2553/4885CYP3A4 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.